Dogwood Therapeutics, Inc. (DWTX) Income Statement
DWTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsDWTX revenue and net income
DWTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
DWTX quarterly EPS vs estimates
Dogwood Therapeutics beat the analyst EPS estimate in 2 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.15).
DWTX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $12,177 | — | — | — | — | — | — |
| Gross profit | — | −$12,177 | — | — | — | — | — | — |
| Research & development | $21.9M | $3.5M | $1.7M | $8.1M | $10.8M | $194,013 | $800,620 | $854,109 |
| Sales, general & admin | $6.1M | $8.7M | $3.7M | $4.2M | $4.8M | $9.8M | $1.4M | $1.1M |
| Total operating expenses | $28.0M | $12.2M | $5.4M | $12.3M | $15.6M | $10.0M | $2.2M | $2.0M |
| Operating income | −$28.0M | −$12.2M | −$5.4M | −$12.3M | −$15.6M | −$10.0M | −$2.2M | −$2.0M |
| Interest income | — | — | $150,904 | $67,475 | — | — | — | — |
| Interest expense | — | $92,192 | — | — | — | $384,222 | $295,128 | $152,103 |
| Income before taxes | −$34.0M | −$12.4M | −$5.3M | −$12.2M | −$16.0M | −$10.3M | −$2.5M | −$2.1M |
| Income taxes | $221,096 | −$503 | — | — | — | — | — | — |
| Net income | −$34.3M | −$12.3M | −$5.3M | −$12.2M | −$16.0M | −$10.3M | −$2.5M | −$2.1M |
| EBITDA | −$34.0M | −$12.2M | −$5.3M | −$12.2M | −$16.0M | −$10.0M | −$2.2M | −$2.0M |
| EPS (diluted) | −$18.90 | −$11.34 | −$3.64 | −$32.75 | −$34.79 | −$1.68 | −$12.80 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $16,686 | — | — | — | $17,256 | $17,022 | $12,177 | — | — | — | — | — |
| Gross profit | −$16,686 | — | — | — | −$17,256 | −$17,022 | −$12,177 | — | — | — | — | — |
| Research & development | $3.2M | $2.7M | $2.3M | $14.5M | $2.6M | $2.4M | $2.3M | $535,162 | $336,084 | $343,717 | $298,321 | $374,200 |
| Sales, general & admin | $1.6M | $2.4M | $1.5M | $1.3M | $1.4M | $2.0M | $5.2M | $1.8M | $733,740 | $970,384 | $839,805 | $900,089 |
| Total operating expenses | $4.9M | $5.1M | $3.8M | $15.8M | $3.9M | $4.4M | $7.5M | $2.3M | $1.1M | $1.3M | $1.1M | $1.3M |
| Operating income | −$4.9M | −$5.1M | −$3.8M | −$15.8M | −$3.9M | −$4.4M | −$7.5M | −$2.3M | −$1.1M | −$1.3M | −$1.1M | −$1.3M |
| Interest income | — | — | — | — | — | — | — | $20,488 | $19,991 | $22,766 | $34,953 | $39,215 |
| Interest expense | — | — | — | — | — | $147,090 | $155,437 | — | — | — | — | — |
| Income before taxes | −$14.0M | −$5.0M | −$3.7M | −$15.7M | −$3.8M | −$10.7M | −$7.7M | −$2.3M | −$1.0M | −$1.3M | −$1.1M | −$1.2M |
| Income taxes | −$2.5M | −$1,193 | $31,841 | −$1,436 | $149 | $190,542 | −$503 | — | — | — | — | — |
| Net income | −$11.5M | −$5.0M | −$3.8M | −$15.7M | −$3.8M | −$10.9M | −$7.7M | −$2.3M | −$1.0M | −$1.3M | −$1.1M | −$1.2M |
| EBITDA | −$4.9M | −$5.0M | −$3.7M | −$15.7M | −$3.8M | −$10.6M | −$7.6M | −$2.3M | −$1.0M | −$1.3M | −$1.1M | −$1.2M |
| EPS (diluted) | −$0.34 | −$0.15 | −$0.26 | −$8.20 | −$1.99 | −$8.45 | −$6.29 | −$2.05 | −$1.25 | −$1.75 | −$0.06 | −$1.50 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in DWTX's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
DWTX financial results
Dogwood Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $34.3 million. Diluted earnings per share came to −$18.90.
See the DWTX stock overview for the latest quote and news, or the DWTX chart for price history and technical indicators.
DWTX income statement FAQ
Does Dogwood Therapeutics have revenue?
Dogwood Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Dogwood Therapeutics profitable?
No. Dogwood Therapeutics reported a net loss of $34.3 million in fiscal 2025.
How much does Dogwood Therapeutics spend on research and development?
Dogwood Therapeutics spent $21.9 million on research and development in fiscal 2025.
What are Dogwood Therapeutics's earnings per share?
Dogwood Therapeutics earned $-18.90 per diluted share in fiscal 2025, compared with $-11.34 a year earlier.
When will Dogwood Therapeutics report its next earnings?
Dogwood Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026.
When does Dogwood Therapeutics's fiscal year end?
Dogwood Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.